Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: A retrospective cohort study
Evans et al.,
Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital..,
Journal of Infection, doi:10.1016/j.jinf.2023.02.012
Retrospective high risk outpatients in the UK, showing lower hospitalization/death with molnupiravir treatment. Residual confounding is likely with adjustments having no detail on specific comorbidities.
Concerns have been raised that the mutagenic mechanism of action may create dangerous variants or cause cancer [Hadj Hassine, Swanstrom]. See [Fountain-Jones, Sanderson, ] for analysis of variants potentially created by molnupiravir.
risk of death/hospitalization, 51.0% lower, HR 0.49, p = 0.008, treatment 359, control 4,973, Cox proportional hazards.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Evans et al., 25 Jan 2023, retrospective, United Kingdom, peer-reviewed, 11 authors, study period 16 December, 2021 - 22 April, 2022.
Contact:
andrew.evans@gov.wales, cathy.qi@swansea.ac.uk, j.o.adebayo@swansea.ac.uk, underwoodj7@cardiff.ac.uk, coulsonjm@cardiff.ac.uk, r.bailey@swansea.ac.uk, gareth.john@wales.nhs.uk, edwardsag@cardiff.ac.uk, coopera8@cardiff.ac.uk, r.a.lyons@swansea.ac.uk, a.akbari@swansea.ac.uk.
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2023.01.24.23284916; this version posted January 25, 2023. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .
Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on
preventing hospital admission among higher-risk patients with COVID-19 in Wales: a
retrospective cohort study
Authors
Andrew Evans, Chief Pharmaceutical Officer, Health and Social Services Group, Welsh Government,
Cathays Park, Cardiff CF10 3NQ (corresponding author) Andrew.Evans@gov.wales
Cathy Qi, Statistician and Research Officer, Population Data Science, Swansea University Medical
School, Faculty of Medicine, Health and Life Science, Swansea University, Singleton Park Swansea
SA2 8PP Cathy.Qi@swansea.ac.uk
Lolu Adebayo, Research Officer, Population Data Science, Swansea University Medical School,
Faculty of Medicine, Health and Life Science, Swansea University, Singleton Park Swansea SA2 8PP
J.O.Adebayo@swansea.ac.uk
Jonathan Underwood, Clinical Academic Research Partnership Fellow, School of Medicine, Cardiff
University, University Hospital of Wales, Heath Park, Cardiff, CF14 4XN
underwoodj7@cardiff.ac.uk
James Coulson, Clinical Reader, School of Medicine, Cardiff University, University Hospital of
Wales, Heath Park, Cardiff, CF14 4XN Coulsonjm@cardiff.ac.uk
Rowena Bailey, Senior Research Officer, Population Data Science, Swansea University Medical
School, Faculty of Medicine, Health and Life Science, Swansea University, Singleton Park Swansea
SA2 8PP r.bailey@swansea.ac.uk
Gareth John, Information Systems Development and Design Lead, Information Services Directorate,
Digital Health and Care Wales, Tŷ Glan-yr-Afon, 21 Cowbridge Road East, Cardiff CF11 9AD
Gareth.John@wales.nhs.uk
Adrian Edwards, Professor of General Practice, Division of Population Medicine, Director, PRIME
Centre Wales and Wales COVID-19 Evidence Centre. Division of Population Medicine, Cardiff
University, Neuadd Meirionnydd, Heath Park, Cardiff, CF14 4YS Edwardsag@cardiff.ac.uk
Alison Cooper, Associate Academic Fellow, Wales Covid-19 Evidence Centre. Division of
Population Medicine, Cardiff University, Neuadd Meirionnydd, Heath Park, Cardiff, CF14 4YS
Coopera8@cardiff.ac.uk
Ronan A Lyons, Clinical Professor of Public Health, Population Data Science, Swansea University
Medical School, Faculty of Medicine, Health and Life Science, Swansea University, Singleton Park
Swansea SA2 8PP r.a.lyons@swansea.ac.uk
Ashley Akbari, Associate Professor Population Data Science Research, Population Data Science,
Swansea University Medical School, Faculty of Medicine, Health and Life Science, Swansea
University, Singleton Park Swansea SA2 8PP a.akbari@swansea.ac.uk
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
medRxiv preprint doi: https://doi.org/10.1101/2023.01.24.23284916; this version posted January 25, 2023. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .
Abstract
Objective
To compare the effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab with..
evans2
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit